Many studies have demonstrated that TBS can predict fragility fractures in cases of secondary osteoporosis caused by various conditions such as type I and II diabetes, hyperparathyroidism, Cushing’s syndrome, growth hormone deficiency, post-menopause hormone therapy, rheumatoid arthritis, spondyloarthritis, sarcopenia, chronic kidney disease, long-term glucocorticoid therapy, HIV infection, therapy with aromatase inhibitors, and neurofibromatosis [20,34]. This evidence concerns the gene CYP19A1 and neurofibromatosis.